NK cell immunometabolism as target for liver cancer therapy.

Autor: Wang J; Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China., Liu X; Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing 314000, Zhejiang, China., Jin T; Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China., Cao Y; Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China., Tian Y; Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China., Xu F; Department of General Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China. Electronic address: fxu@cmu.edu.cn.
Jazyk: angličtina
Zdroj: International immunopharmacology [Int Immunopharmacol] 2022 Nov; Vol. 112, pp. 109193. Date of Electronic Publication: 2022 Sep 07.
DOI: 10.1016/j.intimp.2022.109193
Abstrakt: Natural killer (NK) cells are being used effectively as a potential candidate in tumor immunotherapy. However, the migration and transport of NK cells to solid tumors is inadequate. NK cell dysfunction, tumor invasiveness, and metastasis are associated with altered metabolism of NK cells in the liver cancer microenvironment. However, in liver cancers, metabolic impairment of NK cells is still not understood fully. Evidence from various sources has shown that the interaction of NK cell's immune checkpoints with its metabolic checkpoints is responsible for the regulation of the development and function of these cells. How immune checkpoints contribute to metabolic programming is still not fully understood, and how this can be beneficial needs a better understanding, but they are emerging to be incredibly compelling to rebuilding the function of NK cells in the tumor. It is expected to represent a potential aim that focuses on improving the efficacy of therapies based on NK cells for treating liver cancer. Here, the recent advancements made to understand the NK cell's metabolic reprogramming in liver cancer have been summarized, along with the possible interplay between the immune and the metabolic checkpoints in NK cell function. Finally, an overview of some potential metabolic-related targets that can be used for liver cancer therapy treatment has been presented.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: